TG Therapeutics, Inc. (TGTX) Stock Price

TGTXStock
$55.42+90.22%52W
Market Cap$8.48B
P/E16.41x
PEG Ratio1.61
Div yield
Beta1.80

TGTX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)80.37%
Price vs S&P 500 (4W)-0.97%
PEG Ratio1.61
VGM Score62.33
P/E Ratio (Annual)16.41x

TGTX Earnings Surprise History

Q2 250.17est. 0.29
Q3 250.16est. 0.22
Q4 250.14est. 0.33
Q1 260.18est. 0.28
Q2 260.05est. 0.44

TGTX Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
3.93
3.93
3.93
4.00

Industry Peers — Pharmaceuticals(571)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
TGTXTG Therapeutics, Inc.
DBA$55.42
LLYEli Lilly & Co.DBB$1233.66
JNJJohnson & JohnsonDCB$273.14
ABBVABBVIE INC.DCB$265.79
MRKMerck & Co., Inc.DCA$156.45
NVSNovartis AGCCC$159.98
AZNAstraZeneca PLCCBC$169.66
NVONovo-Nordisk A/SBCC$48.66
ABTAbbott LaboratoriesCCB$116.13
PFEPfizer Inc.CDC$28.57
VRTXVertex Pharmaceuticals IncDCB$552.85

About TG Therapeutics, Inc.

TG Therapeutics is a biopharmaceutical company specializing in B-cell disease treatments, with FDA-approved BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis generating revenue primarily in the United States. The company is advancing a pipeline of early-stage therapies including TG-1701 (BTK inhibitor), Azer-Cel (CAR T-cell therapy), and TG-1801 (bispecific antibody) for various B-cell disorders.